Inogen (NASDAQ:INGN) is scheduled to post its quarterly earnings results before the market opens on Wednesday, August 7th. Analysts expect Inogen to post earnings of $0.50 per share for the quarter. Inogen has set its FY 2019 guidance at EPS.
Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, May 7th. The medical technology company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.05). The company had revenue of $90.20 million for the quarter, compared to analyst estimates of $89.69 million. Inogen had a net margin of 12.56% and a return on equity of 15.59%. Inogen’s quarterly revenue was up 14.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.48 EPS. On average, analysts expect Inogen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
NASDAQ:INGN traded down $0.09 during trading hours on Wednesday, reaching $63.09. 7,247 shares of the company traded hands, compared to its average volume of 315,372. The firm’s 50-day simple moving average is $64.69. The stock has a market capitalization of $1.39 billion, a PE ratio of 27.40, a P/E/G ratio of 2.43 and a beta of 1.45. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.70 and a current ratio of 7.35. Inogen has a 1-year low of $56.83 and a 1-year high of $287.79.
A number of equities research analysts have commented on the company. Needham & Company LLC upgraded Smart Global from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a report on Friday, June 28th. BidaskClub lowered Woodward, Inc.Common Stock from a “strong-buy” rating to a “buy” rating in a research note on Saturday. JPMorgan Chase & Co. increased their price target on from GBX 385 ($5.03) to GBX 480 ($6.27) and gave the stock an “overweight” rating in a research note on Wednesday, July 3rd. Finally, Stifel Nicolaus raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and increased their price target for the stock from $11.00 to $17.00 in a research note on Wednesday, May 8th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Inogen presently has a consensus rating of “Hold” and a consensus price target of $117.60.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Story: Lock-Up Period Expiration
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.